脓毒症中的β1受体阻滞剂
本文综述超短效β1受体阻滞剂在脓毒症患者中的代谢与血流动力学效应及临床证据。近期一项Meta分析显示,超短效β1受体阻滞剂可降低持续心动过速脓毒症患者的死亡率,但机制尚不完全清楚。另一项Meta分析报告其增加每搏量指数、降低心率,24小时心指数、平均动脉压和去甲肾上腺素需求不变,心血管效率改善。近期研究提示在脓毒性休克极早期快速滴定艾司洛尔控制心率会导致血流动力学不稳定,故应在完成初始复苏后启动。一项多数为窦性心动过速患者的随机对照试验提示超短效β1受体阻滞剂有死亡率获益。
要点
- 近期Meta分析显示,超短效β1受体阻滞剂降低持续心动过速脓毒症患者的死亡率。
- 另一项Meta分析报告超短效β1受体阻滞剂增加每搏量指数、降低心率,24小时心指数、平均动脉压和去甲肾上腺素需求不变。
- 近期研究报道,在脓毒性休克极早期快速滴定艾司洛尔降低心率会导致血流动力学不稳定,提示应在完成初始复苏后启动超短效β1受体阻滞剂。
- 一项多数为窦性心动过速患者的随机对照试验提示超短效β1受体阻滞剂有死亡率获益。
- 脓毒症高乳酸血症可能更多与氧利用障碍而非氧输送减少有关,β1受体阻滞剂对乳酸动力学的影响尚不明确,需进一步研究。
适用人群与场景
- 脓毒症合并持续心动过速的患者
- 脓毒症合并窦性心动过速的患者
- 应在完成初始复苏后使用超短效β1受体阻滞剂,极早期(脓毒性休克极早期)快速滴定艾司洛尔会导致血流动力学不稳定
处置流程与药物剂量
- 超短效β1受体阻滞剂应在完成初始复苏后启动,用于控制脓毒症患者的窦性心动过速
- 在脓毒性休克极早期快速滴定艾司洛尔降低心率会导致血流动力学不稳定
红旗征与不能漏的情况
- 脓毒性休克极早期快速滴定艾司洛尔降低心率会导致血流动力学不稳定
研究设计与关键结果
- 近期一项Meta分析显示,超短效β1受体阻滞剂降低持续心动过速脓毒症患者的死亡率
- 另一项Meta分析报告,超短效β1受体阻滞剂增加每搏量指数、降低心率,24小时心指数、平均动脉压和去甲肾上腺素需求不变,心血管效率改善
- 近期研究报道,脓毒性休克极早期快速滴定艾司洛尔降低心率导致血流动力学不稳定
- 一项随机对照试验中多数患者为窦性心动过速,结果提示超短效β1受体阻滞剂有死亡率获益
证据类型、等级与局限
- 证据类型:综述
- 超短效β1受体阻滞剂改善死亡率的机制尚不完全清楚
- β1受体阻滞剂在乳酸生成中的作用尚不明确,需开展研究探讨β1受体阻滞剂对乳酸动力学的影响
- 仍需更大规模随机对照试验阐明超短效β1受体阻滞剂的效果
对床旁实践的改变
- 作者认为,在完成初始复苏后使用超短效β1受体阻滞剂控制窦性心动过速仍然是合理的
- 许多临床医生仍不习惯控制窦性心动过速
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The use of ultrashort-acting β1-blockers recently has attracted attention in septic patients with non-compensatory tachycardia. We summarized the metabolic and hemodynamic effects and the clinical evidence of ultrashort-acting β1-blockers.
MAIN BODY: A recent meta-analysis showed that ultrashort-acting β1-blockers reduced the mortality in septic patients with persistent tachycardia. However, its mechanism to improve mortality is not fully understood yet. We often use lactate as a marker of oxygen delivery, but an impaired oxygen use rather than reduced oxygen delivery has been recently proposed as a more reasonable explanation of hyperlactatemia in patients with sepsis, leading to a question of whether β1-blockers affect metabolic systems. While the stimulation of the β2-receptor accelerates glycolysis and lactate production, the role of β1-blocker in lactate production remains unclear and studies investigating the role of β1-blockers in lactate kinetics are warranted. A meta-analysis also reported that ultrashort-acting β1-blockers increased stroke volume index, while it reduced heart rate, resulting in unchanged cardiac index, mean arterial pressure, and norepinephrine requirement at 24 h, leading to an improvement of cardiovascular efficiency. On the other hand, a recent study reported that heart rate reduction using fast esmolol titration in the very early phase of septic shock caused hemodynamic instability, suggesting that ultrashort-acting β1-blockers should be started only after completing initial resuscitation. While many clinicians still do not feel comfortable controlling sinus tachycardia, one randomized controlled trial in which the majority had sinus tachycardia suggested the mortality benefit of ultrashort-acting β1-blockers. Therefore, it still deems to be reasonable to control sinus tachycardia with ultrashort-acting β1-blockers after completing initial resuscitation.
CONCLUSION: Accumulating evidence is supporting the use of ultrashort-acting β1-blockers while larger randomized controlled trials to clarify the effect of ultrashort-acting β1-blockers are still warranted.
参考来源
- Hasegawa D, Sato R, Nishida O, et al. β1-blocker in sepsis. J Intensive Care. 2021. PMID: 33964987. doi:10.1186/s40560-021-00552-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。